Abstract
Considerable insight into the problem of drug resistance has emerged in the past few years. An understanding of why tumors develop drug resistance is now at hand both from theoretical points of view and from experimental and clinical data. Experimental models of drug resistance, particularly related to the surface P-glycoprotein, have been remarkably successful in teaching us why tumor cells in culture develop resistance to common therapeutic agents. In this panel discussion, the clinical relevance of these and other proposed mechanisms will be examined, with the hope of providing an up-to-date overview on this exciting field.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Additional information
A series of teleconferences has been organized under the auspices of Bristol-Myers to address several major current questions in oncology. A panel of recognized experts with a moderator has been assembled to discuss each question, and we are reporting a number of these discussions in Breast Cancer Research and Treatment. This is reprinted from ‘Ocology Viewpoints’, courtesy of Bristol-Myers Oncology Division, Evansville IN 47721, USA.
Rights and permissions
About this article
Cite this article
McGuire, W.L., Fojo, A., Goldie, J.H. et al. Chemotherapy drug resistance — a panel discussion. Breast Cancer Res Tr 10, 133–144 (1987). https://doi.org/10.1007/BF01810576
Issue Date:
DOI: https://doi.org/10.1007/BF01810576